INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD. Financials Innovita Biological Technology Co., Ltd.
Equities
688253
CNE100005Q14
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.9 CNY | +0.76% |
|
-2.85% | +63.53% |
| 04-15 | Innovita Biological Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-12 | China stocks track Asian markets lower on rate concerns | RE |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 3,241 | 3,403 |
| Enterprise Value (EV) 1 | 1,761 | 1,709 |
| P/E ratio | 19.2 x | 19.5 x |
| Yield | 0.7% | 1.6% |
| Capitalization / Revenue | 7.26 x | 7.12 x |
| EV / Revenue | 3.94 x | 3.57 x |
| EV / EBITDA | 15.5 x | 8.51 x |
| EV / FCF | 39,377,737 x | 9,556,907 x |
| FCF Yield | 0% | 0% |
| Price to Book | 1.92 x | 1.85 x |
| Nbr of stocks (in thousands) | 136,061 | 136,061 |
| Reference price 2 | 23.82 | 25.01 |
| Announcement Date | 3/30/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 78.83 | 138 | 1,034 | 326.9 | 446.6 | 478 |
| EBITDA 1 | 19.88 | 29.88 | 708.5 | 145.2 | 113.6 | 200.8 |
| EBIT 1 | 17.59 | 27.43 | 703.1 | 132.1 | 94.59 | 178.9 |
| Operating Margin | 22.32% | 19.88% | 68.03% | 40.41% | 21.18% | 37.43% |
| Earnings before Tax (EBT) 1 | 18.16 | 29.17 | 672 | 137.8 | 164.5 | 198.4 |
| Net income 1 | 16.97 | 23.74 | 569 | 120.3 | 150.7 | 173.9 |
| Net margin | 21.52% | 17.2% | 55.05% | 36.78% | 33.74% | 36.39% |
| EPS | - | - | 5.740 | 1.180 | 1.240 | 1.280 |
| Free Cash Flow | - | 18.31 | 400.9 | -5.835 | 44.72 | 178.8 |
| FCF margin | - | 13.27% | 38.79% | -1.78% | 10.01% | 37.41% |
| FCF Conversion (EBITDA) | - | 61.27% | 56.58% | - | 39.37% | 89.03% |
| FCF Conversion (Net income) | - | 77.12% | 70.46% | - | 29.67% | 102.79% |
| Dividend per Share | - | - | - | - | 0.1660 | 0.4000 |
| Announcement Date | 6/16/21 | 6/16/21 | 6/16/21 | 7/10/22 | 3/30/23 | 4/15/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 52.4 | 101 | 588 | 566 | 1,480 | 1,694 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 18.3 | 401 | -5.83 | 44.7 | 179 |
| ROE (net income / shareholders' equity) | - | 26.7% | 145% | 17.1% | 12.4% | 9.85% |
| ROA (Net income/ Total Assets) | - | 13.3% | 93.5% | 10.5% | 4.31% | 5.58% |
| Assets 1 | - | 178.4 | 608.5 | 1,149 | 3,492 | 3,117 |
| Book Value Per Share | - | - | 6.740 | 7.230 | 12.40 | 13.50 |
| Cash Flow per Share | - | - | 4.860 | 4.700 | 2.860 | 1.220 |
| Capex 1 | 5.3 | 10.3 | 76.7 | 63.7 | 57.7 | 17 |
| Capex / Sales | 6.72% | 7.44% | 7.42% | 19.5% | 12.92% | 3.55% |
| Announcement Date | 6/16/21 | 6/16/21 | 6/16/21 | 7/10/22 | 3/30/23 | 4/15/24 |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +63.53% | 765M | |
| -4.77% | 12.32B | |
| -5.19% | 8.07B | |
| +30.21% | 5.52B | |
| -7.35% | 4.21B | |
| -54.88% | 2.99B | |
| +13.49% | 2.73B | |
| -3.75% | 2.43B | |
| +31.50% | 2.29B | |
| -3.55% | 1.89B |
- Stock Market
- Equities
- 688253 Stock
- Financials Innovita Biological Technology Co., Ltd.